🔗 Share this article

An underground economy for unapproved slimming drugs is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.

Investigational Drug Acquiring Popularity Online

The experimental drug, which is still in clinical trials, is being promoted by online personalities for its alleged weight-reducing properties. Viewers are urged to message these accounts privately for supplier links, while also obtaining discount codes.

Thriving Commerce on Messaging Platforms

Separately, a robust trade exists on messaging services, where communities with thousands of members share comparison photos, injection guides and claims of rapid British shipping. Sellers promote the substance there before directing buyers to other platforms for purchases.

Understanding Retatrutide

Retatrutide is an experimental injectable developed by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could assist individuals lose up to 25% of their body weight. Nicknamed the “triple G”, the drug is being hailed online as the next Ozempic.

Medical Experts Voice Concerns

Nevertheless, doctors and pharmacists have warned that the sale of what remains an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals injecting products of unknown origin.

Some experts said the demand for the experimental drug could be connected to the rising price of approved weight loss treatments such as Mounjaro.

Legal Status and Enforcement

Marketing retatrutide on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Several content creators try to sidestep the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but advertising and distribution can still violate pharmaceutical, advertising, and consumer laws, potentially leading to fines, legal action or imprisonment.

Service Response and Content Elimination

Based on TikTok, the service has removed problematic content and banned associated hashtags and search suggestions. The company said it was dedicated to keeping the platform secure and investing in enhancing enforcement strategies.

Digital Marketplace Operations

Investigations also found groups with up to nine thousand members selling the experimental drug using the platform's integrated discovery tool, which functions like a public directory. Typing “retatrutide” immediately displays groups with numerous of members, filled with photos of weight loss, glowing reviews and detailed guides for mixing or administering at home.

After moments of joining one community, a vendor posted contact information, where the majority of transactions occur. The vendor sent an instruction manual and guaranteed shipping within two days. When questioned whether the substance was authentic, one vendor said: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. None inquired about body mass, medical conditions or previous experience.

Item Information and Pricing

Inside these groups, messages display black plastic packages with Royal Mail labels, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with purified liquid, or ready-to-use injectors typically sold at 160 pounds for 20mg. When questioned how long a pen should be used, vendors give contradictory responses ranging from a several days to “depends on your body”.

Service Oversight and Safety Actions

A representative for the messaging service said it regularly moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are administering materials they cannot confirm. Although the science behind retatrutide is valid, these digital versions may not contain what they claim,” stated Jason Murphy, the head of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to current cost increases for authorized weight-loss medications such as Mounjaro. “With prices rising, patients are using online platforms. But fake treatments are extremely risky. You can’t be certain what’s inside or whether the environment they were made in was clean,” she explained.

Her team has already encountered patients harmed by personal administration from unconfirmed sources. “We understand the frustration, but buying from Telegram or WhatsApp is gambling with your health,” said Wyllie. “These substances could be impure or improperly measured.”

Manufacturer Position

A representative from Eli Lilly stated the substance was in third stage clinical trials and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Consequently at this point no one can market [it] for human use,” they explained, adding that any product “misleadingly claiming itself as a Lilly investigational product not yet authorized … may expose patients to possibly significant medical dangers”.